Previous 10 | Next 10 |
home / stock / hnsbf / hnsbf news
press release ( OTCPK:HNSBF ): 1H GAAP EPS of -SEK6.94. Revenue of SEK56.7M (+320.0% Y/Y). For further details see: GAAP EPS of -SEK6.94, revenue of SEK56.7M
Hansa Biopharma AB press release ( OTCPK:HNSBF ): Q2 GAAP EPS of -SEK 3.82. Revenue of SEK 26.4M (+486.7% Y/Y). For further details see: Hansa Biopharma AB GAAP EPS of -SEK 3.82, revenue of SEK 26.4M
Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company's antibody-cleaving enzyme technology platform PR Newswire Proceeds will be mainly utilized to: - Further strengthen th...
The Nomination Committee in Hansa Biopharma proposes Peter Nicklin as new chair of the Board of Directors at the Annual General Meeting 2022 PR Newswire The Nomination Committee in Hansa Biopharma has completed its nomination work for the Annual General Meeting 2022. I...
The following slide deck was published by Hansa Biopharma AB (publ) in conjunction with their 2022 Q1 earnings call. For further details see: Hansa Biopharma AB (publ) 2022 Q1 - Results - Earnings Call Presentation
Hansa Biopharma AB (publ) (HNSBF) Q1 2022 Earnings Conference Call April 21, 2022 8:00 AM ET Company Participants Søren Tulstrup – Chief Executive Officer Conference Call Participants Adam Karlsson – ABG Douglas Tsao – H.C. Wainwright Christopher Uhde – SEB Do...
Hansa Biopharma AB press release (OTC:HNSBF): Q1 GAAP EPS of -SEK3.11. Revenue of SEK30.3M (+236.7% Y/Y). For further details see: Hansa Biopharma AB GAAP EPS of -SEK3.11, revenue of SEK30.3M
Hansa Biopharma announces positive early access decision by French Haute Autorité de Santé to use Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients PR Newswire - Decision to use commercially supplied ...
Hansa Biopharma AB (publ) (HNSBF) Q4 2021 Earnings Conference Call February 3, 2022 8:0 a.m. ET Company Participants Søren Tulstrup - President & CEO Donato Spota - CFO Klaus Sindahl - IR Conference Call Participants Christopher Uhde - SEB Adam Karlsson - ABG Sundal Collier Johan Unn...
The following slide deck was published by Hansa Biopharma AB (publ) in conjunction with their 2021 Q4 earnings call. For further details see: Hansa Biopharma AB (publ) 2021 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Hansa Biopharma AB Company Name:
HNSBF Stock Symbol:
OTCMKTS Market:
Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting PR Newswire LUND , Sweden , May 21, 2024 /PRNewswire/ --. Hansa Biopharma, "Hansa" (NASDAQ: HNSA) (STOCKHOLM: HNSA), today announced data featuring imlifidase will be present...
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation PR Newswire Statistically significant reduction in donor-specific antibodies (DSAs) observed among imlifidase patients within five days of treatment as compared ...
Hansa Biopharma interim report January-March 2023 PR Newswire Positive reimbursement decision in Spain expands market access to include the five largest European markets Enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS) completed HNSA-...